Currently, there are 46.48M common shares owned by the public and among those 44.73M shares have been available to trade.
The company’s stock has a 5-day price change of -39.10% and -58.23% over the past three months. PCRX shares are trading -63.57% year to date (YTD), with the 12-month market performance down to -67.50% lower. It has a 12-month low price of $11.70 and touched a high of $39.19 over the same period. PCRX has an average intraday trading volume of 1.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -39.23%, -49.24%, and -56.44% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Pacira BioSciences Inc (NASDAQ: PCRX) shares accounts for 111.39% of the company’s 46.48M shares outstanding.
It has a market capitalization of $566.94M and a beta (3y monthly) value of 0.96. The stock’s trailing 12-month PE ratio is 9.55, while the earnings-per-share (ttm) stands at $1.29. The company has a PEG of 0.88 and a Quick Ratio of 5.70 with the debt-to-equity ratio at 0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 26.95% over the week and 10.45% over the month.
Earnings per share for the fiscal year are expected to increase by 7.65%, and 5.68% over the next financial year.
Looking at the support for the PCRX, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on August 12, 2024, with the firm’s price target at $37-$14. Piper Sandler was of a view on August 12, 2024 that the stock is Neutral, while JP Morgan gave the stock Underweight rating on August 12, 2024, issuing a price target of $45- $10. Barclays on their part issued Equal Weight rating on July 03, 2024.
